

# **Prof. ARZU BEŞİKÇİ**

## **Personal Information**

**Office Phone:** [+90 312 203 3133](tel:+903122033133)

**Email:** abesikci@ankara.edu.tr

**Web:** <https://avesis.ankara.edu.tr/abesikci>

## **International Researcher IDs**

ORCID: 0000-0001-6883-1757

Yoksis Researcher ID: 120323

## **Education Information**

Doctorate, University of Alberta, Faculty Of Medicine, Canada 1998 - 2003

Postgraduate, Ankara University, Sağlık Bilimleri Enstitüsü, Farmakoloji (Yıl) (Tezli), Turkey 1994 - 1997

Undergraduate, Hacettepe University, Eczacılık Fakültesi, Eczacılık Pr., Turkey 1989 - 1994

## **Dissertations**

Doctorate, Maturation of Fatty Acid Oxidation in Newborn Rabbit Heart, University of Alberta, Faculty Of Medicine, 2003

Postgraduate, Endotel, Ankara University, Sağlık Bilimleri Enstitüsü, Farmakoloji (Yıl) (Tezli), 1997

## **Academic Titles / Tasks**

Professor, Ankara University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, 2014 - Continues

Associate Professor, Ankara University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, 2009 - 2014

Research Assistant, Ankara University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, 1996 - 2010

## **Academic and Administrative Experience**

Ankara University, 2016 - Continues

Ankara University, 2014 - 2015

## **Courses**

Pharmacology II, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021

Pharmacology I, Undergraduate, 2023 - 2024

Pharmacotherapeutics, Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021

Pharmacology III, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021

OTC Drugs, Undergraduate, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020

Pharmacology, Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020

## AÖVİSİNG İNESESİ

- BEŞİKÇİ A., İvabradinin kardiyovasküler pleiotropik etkilerinin ve bu etkilere aracılık eden mekanizmaların streptozotosin diyabet modelinde incelenmesi, Doctorate, Z.KARA(Student), 2020
- BEŞİKÇİ A., Karvedilolin metabolik ve kardiyovasküler etkilerine beta-arrestinlerin katkısının incelenmesi, Doctorate, B.GÜVEN(Student), 2019
- BEŞİKÇİ A., Beta adrenerjik reseptör blokeri ilaçların kalbin substrat metabolizması üzerindeki etkilerinin miyosit hücre kültürlerinde incelenmesi, E.SÜZMEÇELİK(Student), 2011

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Past and present of beta arrestins: A new perspective on insulin secretion and effect.**  
GÜVEN B., Onay-Besikci A.  
European journal of pharmacology, vol.956, pp.175952, 2023 (SCI-Expanded)
- II. **A no-filter snapshot of drug-related problems in Ankara University Hospitals**  
TEZGELEN A. S., KAYRA T., ÜRKMEZ F., Akyol B., TOPALOĞLU İ. E., RAHVAN H., KAHRAMAN S., DAL M. A., DEDE M., Onay-Besikci A.  
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol.44, no.3, pp.797, 2022 (SCI-Expanded)
- III. **Synthesis, molecular docking, in silico ADME, and EGFR kinase inhibitor activity studies of some new benzimidazole derivatives bearing thiosemicarbazide, triazole, and thiadiazole**  
ÇELİK İ., Ayhan-Kilcigil G., Karayel A., GÜVEN B., BEŞİKÇİ A.  
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol.59, no.2, pp.371-387, 2022 (SCI-Expanded)
- IV. **Pleiotropic vascular effects of ivabradine in streptozotocin-induced diabetes**  
Kara Z., GÜVEN B., BEŞİKÇİ A., YILDIRIM N., ALTUNAY H.  
EUROPEAN JOURNAL OF PHARMACOLOGY, vol.916, 2022 (SCI-Expanded)
- V. **Pattern of systemic antibiotic use and potential drug interactions: evaluations through a point prevalence study in Ankara University Hospitals**  
AKDEMİR KALKAN İ., ÇINAR G., PEHLİVANLI A., ÜRKMEZ F., TOPALOĞLU İ. E., Akyol B., BEŞİKÇİ A., AZAP A., MEMİKOĞLU K. O.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.2, pp.523-529, 2021 (SCI-Expanded)
- VI. **Metabolic effects of carvedilol through beta-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts**  
GÜVEN B., Kara Z., BEŞİKÇİ A.  
BRITISH JOURNAL OF PHARMACOLOGY, vol.177, no.24, pp.5580-5594, 2020 (SCI-Expanded)
- VII. **Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors**  
ÇELİK İ., KILCIGİL G., GÜVEN B., Kara Z., Gurkan-Alp A. S., KARAYEL A., BEŞİKÇİ A.  
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.173, pp.240-249, 2019 (SCI-Expanded)
- VIII. **QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment**  
AMASYA G., Aksu B., BADILLI F. U., BEŞİKÇİ A., Tarimci N.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.563, pp.110-121, 2019 (SCI-Expanded)
- IX. **THERMOSENSITIVE IN SITU GEL FORMULATION CONTAINING PLGA NANOPARTICLES OF FLURBIPROFEN FOR OCULAR DELIVERY**  
Aydin E., BADILLI F. U., BEŞİKÇİ A., Tarimci N.  
ACTA POLONIAE PHARMACEUTICA, vol.75, no.1, pp.141-153, 2018 (SCI-Expanded)
- X. **Evaluation of three-layered doxycycline-collagen loaded nanofiber wound dressing**  
TORT S., ACARTÜRK F., BEŞİKÇİ A.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.529, no.1-2, pp.642-653, 2017 (SCI-Expanded)
- XI. **Skin Localization of Lipid Nanoparticles (SLN/NLC): Focusing the Influence of Formulation Parameters**  
AMASYA G., Sandri G., BEŞİKÇİ A., BADILLI F. U., Caramella C., Bonferoni M. C., Tarimci N.  
CURRENT DRUG DELIVERY, vol.13, no.7, pp.1100-1110, 2016 (SCI-Expanded)

- XII. **Calcipotriol-captisol inclusion complex and corticosteroid in a novel fixed dose combination: evaluation on human epidermal keratinocyte cells**  
BADILLI F. U., BEŞİKCİ A., AMASYA G., Sen T., Tarimci N.  
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.83, no.3-4, pp.363-368, 2015 (SCI-Expanded)
- XIII. **Activating PPAR alpha Prevents Post-Ischemic Contractile Dysfunction in Hypertrophied Neonatal Hearts**  
Lam V. H., Zhang L., Huqi A., Fukushima A., Tanner B. A., BEŞİKCİ A., Keung W., Kantor P. F., Jaswal J. S., Rebeyka I. M., et al.  
CIRCULATION RESEARCH, vol.117, no.1, pp.41-51, 2015 (SCI-Expanded)
- XIV. **Effect of Fatty Acids on Human Bone Marrow Mesenchymal Stem Cell Energy Metabolism and Survival**  
Fillmore N., Huqi A., Jaswal J. S., Mori J., Paulin R., Haromy A., BEŞİKCİ A., Ionescu L., Thebaud B., Michelakis E., et al.  
PLOS ONE, vol.10, no.3, 2015 (SCI-Expanded)
- XV. **Development of Etofenamate-Loaded Semisolid SLN Dispersions and Evaluation of Anti-Inflammatory Activity for Topical Application**  
BADILLI F. U., ŞENGEL TÜRK C. T., BEŞİKCİ A., Tarimci N.  
CURRENT DRUG DELIVERY, vol.12, no.2, pp.200-209, 2015 (SCI-Expanded)
- XVI. **Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats**  
SEZGİN BAYINDIR Z., BEŞİKCİ A., YÜKSEL N.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.45, no.6, pp.1403-1412, 2015 (SCI-Expanded)
- XVII. **Substrate Metabolism in the Diabetic Heart**  
BEŞİKCİ A.  
DIABETIC CARDIOMYOPATHY: BIOCHEMICAL AND MOLECULAR MECHANISMS, vol.9, pp.65-76, 2014 (SCI-Expanded)
- XVIII. **Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors**  
Dincer S., Cetin K. T., BEŞİKCİ A., Olgen S.  
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol.28, no.5, pp.1080-1087, 2013 (SCI-Expanded)
- XIX. **Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases**  
KILIÇ KURT Z., BEŞİKCİ A., Olgen S.  
LETTERS IN DRUG DESIGN & DISCOVERY, vol.10, no.8, pp.713-718, 2013 (SCI-Expanded)
- XX. **Special Issue: New Trends in Pharmaceutical Sciences 10th International Symposium on Pharmaceutical Sciences (10th ISOPS) June 26 to 29, 2012 Ankara University Faculty of Pharmacy, Ankara-Turkey**  
YÜKSEL N., BEŞİKCİ A.  
CURRENT DRUG DELIVERY, vol.10, no.1, pp.2, 2013 (SCI-Expanded)
- XXI. **Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution**  
SEZGİN BAYINDIR Z., BEŞİKCİ A., VURAL N., YÜKSEL N.  
JOURNAL OF MICROENCAPSULATION, vol.30, no.8, pp.796-804, 2013 (SCI-Expanded)
- XXII. **Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells**  
BEŞİKCİ A., Suzmecelik E., ÖZÇELİKAY A. T.  
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol.90, no.8, pp.1087-1093, 2012 (SCI-Expanded)
- XXIII. **Acute Regulation of Cardiac Metabolism by the Hexosamine Biosynthesis Pathway and Protein O-GlcNAcylation**  
Laczy B., Fueloep N., BEŞİKCİ A., Rosiers C. D., Chatham J. C.  
PLOS ONE, vol.6, no.4, 2011 (SCI-Expanded)

- XXIV. **Protective action of doxycycline against diabetic cardiomyopathy in rats**  
 YARAŞ N., Sarıahmetoglu M., BİLGİNOĞLU A., Aydemir-Koksoy A., BEŞİKÇİ A., Turan B., Schulz R.  
 BRITISH JOURNAL OF PHARMACOLOGY, vol.155, no.8, pp.1174-1184, 2008 (SCI-Expanded)
- XXV. **Trimetazidine revisited: A comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine**  
 BEŞİKÇİ A., Oezkan S. A.  
 Cardiovascular Therapeutics, vol.26, no.2, pp.147-165, 2008 (SCI-Expanded)
- XXVI. **alpha-Lipoic acid increases cardiac glucose oxidation independent of AMP-activated protein kinase in isolated working rat hearts**  
 BEŞİKÇİ A., Wagg C., Lopaschuk T. P., Keung W., Lopaschuk G. D.  
 BASIC RESEARCH IN CARDIOLOGY, vol.102, no.5, pp.436-444, 2007 (SCI-Expanded)
- XXVII. **The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts**  
 BEŞİKÇİ A., Guner S., Arioglu E., ÖZAKCA GÜNDÜZ I., ÖZÇELİKAY A. T., Altan V. M.  
 Canadian Journal of Physiology and Pharmacology, vol.85, no.5, pp.527-535, 2007 (SCI-Expanded)
- XXVIII. **Impact of lactate in the perfusate on function and metabolic parameters of isolated working rat heart**  
 BEŞİKÇİ A.  
 MOLECULAR AND CELLULAR BIOCHEMISTRY, vol.296, no.1-2, pp.121-127, 2007 (SCI-Expanded)
- XXIX. **Substrate metabolism and function of fructose-fed rat heart**  
 Guner S., BEŞİKÇİ A., Arioglu E., ÖZAKCA GÜNDÜZ I., Altan V. M., ÖZÇELİKAY A. T.  
 CARDIOVASCULAR DRUGS AND THERAPY, vol.20, no.6, pp.408, 2006 (SCI-Expanded)
- XXX. **The effects of chronic trimetazidine treatment on mechanical parameters and fatty acid oxidation in 14-week diabetic rat hearts**  
 BEŞİKÇİ A., Guner S., Arioglu E., ÖZAKCA GÜNDÜZ I., Ozcelikay T., Altan V. M.  
 CARDIOVASCULAR DRUGS AND THERAPY, vol.20, no.6, pp.417, 2006 (SCI-Expanded)
- XXXI. **Malonyl CoA control of fatty acid oxidation in the newborn heart in response to increased fatty acid supply**  
 BEŞİKÇİ A., Sambandam N.  
 CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol.84, no.11, pp.1215-1222, 2006 (SCI-Expanded)
- XXXII. **Regulation of cardiac energy metabolism in newborn**  
 BEŞİKÇİ A.  
 MOLECULAR AND CELLULAR BIOCHEMISTRY, vol.287, no.1-2, pp.1-11, 2006 (SCI-Expanded)
- XXXIII. **gAd-globular head domain of adiponectin increases fatty acid oxidation in newborn rabbit hearts**  
 BEŞİKÇİ A., Altarejos J., Lopaschuk G.  
 JOURNAL OF BIOLOGICAL CHEMISTRY, vol.279, no.43, pp.44320-44326, 2004 (SCI-Expanded)
- XXXIV. **Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats**  
 Atkinson L., Kozak R., Kelly S., BEŞİKÇİ A., Russell J., Lopaschuk G.  
 AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, vol.284, no.5, 2003 (SCI-Expanded)

### Articles Published in Other Journals

- I. **SARS-CoV-2 Infection may be Prevented with Cytochrome Inhibitors: Cobicistat and Ritonavir**  
 Gülten E., Çelik İ., Beşikçi A., Çınar G., Akdemir Kalkan İ., Kılçigil G., Memikoğlu K. O., Birengel M. S., Azap A.  
 Infectious diseases and clinical microbiology (Online), vol.4, no.3, pp.185-191, 2022 (Peer-Reviewed Journal)
- II. **HİPERTANSİYON TEDAVİ YÖNETİMİNDE ECZACININ ROLÜ: AİLE SAĞLIĞI MERKEZİ'NDE BİR MODEL UYGULAMASI**  
 PEHLİVANLI A., Akyol B., Sesyılmaz Ö., Göçün Ö., BEŞİKÇİ A., ÖZÇELİKAY A. T., ÖZÇELİKAY G.  
 Journal of Faculty of Pharmacy of Ankara University, vol.45, no.1, pp.1-11, 2021 (Scopus)

- III. Orbital Cellulitis Accompanied by a Non-Symptomatic Drug Interaction That Promptly Responded to Drug Modification**  
 AKDEMİR K. İ., AKYOL B., YILMAZ F., BEŞİKCİ A., MEMİKOĞLU K. O.  
*Turkiye Klinikleri Journal of Case Reports*, vol.27, no.2, pp.95-98, 2019 (Peer-Reviewed Journal)
- IV. Synthesis and Pharmacologic Evaluation of Some Benzimidazole Acetohydrazide Derivatives as EGFR Inhibitors**  
 Demirel S., KILCIGİL G., Kara Z., GÜVEN B., BEŞİKCİ A.  
*TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES*, vol.14, no.3, pp.285-289, 2017 (ESCI)

## Books & Book Chapters

- I. Beta Arrestin**  
 BEŞİKCİ A., GÜVEN B.  
 in: *Kalp Yetersizliği ve Tedavisinde Yeni Hedefler*, , Editor, Türkiye Klinikleri, pp.159-161, 2023
- II. Herpes Enfeksiyonlarında Kullanılan İlaçlar**  
 GÜVEN B., ARSLAN E., BEŞİKCİ A.  
 in: *Viral Enfeksiyonlarda Güncel Tedavi Yaklaşımları ve İmmünizasyon*, Erdinç Meral, Editor, Ortadoğu, Ankara, pp.61-68, 2021
- III. C Vitamini, D Vitamini, Çinko: COVID-19 Tedavisinde Mikro Besinlerden Makro Beklenti Gerçekçi mi?**  
 GÜVEN B., Kara Z., BEŞİKCİ A.  
 in: *Türkiye Klinikleri*, Birengel Serhat, Balık İsmail, Editor, Ortadoğu, Ankara, pp.53-58, 2021
- IV. Türk Farmakopesi II - Avrupa Farmakopesi Adaptasyonu**  
 YÜKSEL N., ÖZKAN S. A., ÖZKAN Y., KILIÇARSLAN M., SÜZEN S., SALTAN H. G., BEŞİKCİ A., SARAÇ TARHAN S., AYDIN A., SÜZEN S., et al.  
 Anil Reklam Matbaa Ltd. Şti. / Ankara, 2016
- V. Substrate Metabolism in the Diabetic Heart**  
 Onay-Besikci A.  
 in: *Diabetic Cardiomyopathy*, Belma Turan and Naranjan S. Dh, Editor, Springer, London/Berlin , New York, pp.65-76, 2013
- VI. Regulation of Fatty Acid Oxidation by Malonyl CoA in Cardiac Muscle Tissue**  
 Onay-Besikci A., Lopaschuk G. D.  
 in: *Advances in Molecular and Cell Biology*, G. van der Vusse, Editor, Elsevier Science, Oxford/Amsterdam , Amsterdam, pp.223-241, 2003

## Refereed Congress / Symposium Publications in Proceedings

- I. Chronic Effects of Carvedilol on Erectile Dysfunction in STZ-Induced Diabetic Rats**  
 GÜVEN ÇİLOĞLU B., YILMAZ ORAL D., KARA Z., GÜR S., BEŞİKCİ A.  
 14. Uluslararası Tip ve Sağlık Bilimleri Araştırmaları Kongresi- UTSAK, Ankara, Turkey, 23 - 24 December 2023
- II. Monitoring vancomycin plasma levels: Pharmacokinetic evaluations and compliance with guidelines**  
 Kahraman Başer S., Topaloğlu I. E., Çınar G., Gülten E., Akdemir Kalkan I., Sarıcaoğlu E. M., Rahvan H., Beşikci A.  
 NORPM2023, Turku, Finland, 14 - 16 June 2023, pp.11
- III. Potential drug interactions in hospitalized patients: Are the evaluations coherent?**  
 Topaloğlu I. E., Beşikci A.  
 NORPM2023, Turku, Finland, 14 - 16 June 2023, pp.11
- IV. Metabolic Effects of Carvedilol on Control and HFpEF Mouse Heart and Hypertrophied H9c2 Cells: The Potential Contribution of a Biased Agonist Effect**  
 GÜVEN B., QIUYU S., PERSAD K. L., WAGG C., OLIVEIRA A. A., SILVER H., ANDRE D. J., BEŞİKCİ A., OUDIT G. Y., Lopaschuk G. D.

ECCR 2022, Treviso, Italy, 30 September - 02 October 2022

- V. **The direct metabolic effects of carvedilol in control mice hearts and hypertrophied H9c2 cells**  
GÜVEN B., WAGG C. S., PERSAD K. L., SUN Q., ANDRE D. J., BEŞİKCİ A., LOPASCHUK G. D.  
Pediatrics Research Day, Edmonton, Canada, 06 April 2022
- VI. **IN VIVO EVALUATION ON FLUTICASONE PROPIONATE LOADED SEMI-SOLID LIPID NANOPARTICLE DISPERSIONS**  
BADILLI F. U., ŞENGEL TÜRK C. T., AMASYA G., ALÇIĞIR M. E., BEŞİKCİ A., AKSU N. B., TARIMCI M. N., HAZIROĞLU R.  
20th International Pharmaceutical Technology Symposium – IPTS 2022, Ankara, Turkey, 21 - 23 February 2022
- VII. **CURCUMIN LOADED SEMISOLID SLN DISPERSIONS: FORMULATION OPTIMIZATION AND IN VIVO EVALUATION**  
KARGILI ŞEN A., BADILLI F. U., YEĞEN G., GÜVEN B., AKSU N. B., BEŞİKCİ A.  
13th International Symposium on Pharmaceutical Sciences (ISOPS-13), Turkey, 22 June 2021
- VIII. **Semisolid NLC dispersions: QbD based formulation optimization and ex vivo – in vivo evaluation**  
AMASYA G., ŞENGEL TÜRK C. T., BADILLI F. U., AKSU N. B., BEŞİKCİ A., TARIMCI M. N.  
EUFEPS Virtual Annual Meeting 2021 – Bridging the gap between the patient and product design, Sweden, 7 - 09 June 2021
- IX. **Design and Synthesis of Some Oxadiazole Bearing Benzimidazole Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors**  
ÇELİK İ., KILCIGİL G., GÜVEN B., BEŞİKCİ A., Kara Z.  
ICMBC 2019 : International Conference on Medicinal and Biological Chemistry, Barselona, Spain, 15 - 16 August 2019
- X. **Metabolic effects of carvedilol through β-arrestin-2: investigations in cells and streptozotocin-diabetic rats**  
GÜVEN B., KARA Z., BEŞİKCİ A.  
17th Annual Meeting of the Society for Heart and Vascular Metabolism (SHVM), 23 - 26 June 2019
- XI. **Presence of HCN Channels in Rat Aorta and Prevention of Endothelial Dysfunction with Their Selective Inhibitor Ivabradine**  
kara z., GÜVEN B., BEŞİKCİ A.  
Pharmacology 2018, Londrina, Brazil, 17 - 19 December 2018
- XII. **Synthesis of Some Thiadiazole/Triazole Linked 1H-Benzimidazole Derivatives As Inhibitors of EGFR Tyrosine Kinase**  
ÇELİK İ., KILCIGİL G., BEŞİKCİ A., kara z., GÜVEN B.  
Eczacılık Kongre ve Fuarı, Paris, France, 20 - 21 August 2018
- XIII. **THE EFFECT OF CARVEDILOL TREATMENT ON ERECTILE DYSFUNCTION IN STREPTOZOTOCIN INDUCED DIABETIC RATS.**  
YILMAZ D., GÜVEN B., KARA Z., GÜR S., BEŞİKCİ A.  
12th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL SCIENCES, Ankara, Turkey, 26 - 29 June 2018
- XIV. **THE POSSIBLE BENEFICIAL EFFECT OF IVABRADINE TREATMENT ON ERECTILE TISSUE IN A DIABETIC RAT MODEL**  
YILMAZ D., KARA Z., GÜVEN B., BEŞİKCİ A., GÜR S.  
12th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL SCIENCES, Ankara, Turkey, 26 - 29 June 2018
- XV. **The mechanism of acute and chronic vascular effects of ivabradine in control and diabetic rats**  
Kara Z., Guven B., BEŞİKCİ A.  
5th Congress of the ESC-Council-on-Basic-Cardiovascular-Science on Frontiers in Cardio Vascular Biology, Vienna, Austria, 20 - 22 April 2018, vol.114
- XVI. **Therapeutic effect of carvedilol on cardiac function in streptozotocin-diabetic rats**  
Guven B., Kara Z., BEŞİKCİ A.  
5th Congress of the ESC-Council-on-Basic-Cardiovascular-Science on Frontiers in Cardio Vascular Biology, Vienna, Austria, 20 - 22 April 2018, vol.114
- XVII. **SYNTHESIS OF SOME 1H-BENZIMIDAZOLES CONTAINING CYCLOHEXYL SUBSTITUTED THIOSEMICARBAZIDES, TRIAZOLES, THIADIAZOLES AS INHIBITORS OF EGFR TYROSINE KINASE**

- ÇELİK İ., KILCIGİL G., Kara Z., GÜVEN B., BEŞİKCİ A.  
GPSS2017, 11 - 13 October 2017
- XVIII. **Investigation of the Pleiotropic Vascular Effects of Ivabradine in Control and Diabetic Rats**  
Kara Z., GÜVEN B., BEŞİKCİ A.  
20th Annual Meeting of European Council for Cardiovascular Resarch, ECCR, Verona, Italy, 14 - 16 October 2016
- XIX. **The effect of leptin treatment on in vivo cardiac parameters of streptozotocin induced diabetic rats**  
ARIOĞLU İNAN E., ERDOĞAN B. R., Müderrisoğlu E., KARAÖMERLİOĞLU İ., KAYKI MUTLU G., BEŞİKCİ A., ALTAN V. M.  
9th Annual Meeting of the Diabetes and Cardiovascular Disease, 30 June - 02 July 2016
- XX. **Timolol improves vascular dysfunction via inhibition of oxidative stresss in DOCAsalt hypertensive rats**  
ÇİÇEK M., ÖZİS S. E., ÖZAKCA I., BEŞİKCİ A., ÖZÇELİKAY A. T.  
7th European Congress of Pharmacology (EPHAR 2016), İstanbul, Turkey, 26 - 30 June 2016
- XXI. **Timolol improves vascular dysfunction via inhibition of oxidative stress in DOCA salt hypertensive rats**  
çiçek m., Özakça I., Erpulat Özış S., BEŞİKCİ A., ÖZÇELİKAY A. T.  
EPHAR 2016, İstanbul, Turkey, 26 - 30 June 2016
- XXII. **Synthesis of Some 1h Benzimidazoles as Inhibitors of EGFR Tyrosine Kinase**  
ÇELİK İ., BEŞİKCİ A., KILCIGİL G.  
World Academy of Science, Engineering and Technology, 27 June 2015 - 28 June 2016
- XXIII. **Lipid Nanoparticle Based Carbopol Gel for Topical Chemotherapy of 5 Fluorouracil**  
AMASYA G., BADILLI F. U., BEŞİKCİ A., TARIMCI M. N.  
Skin Forum, Londrina, Brazil, 21 - 22 June 2016
- XXIV. **In vitro antipsoriatic activity of fixed-dose combination of calcipotriol and clobetasol propionate**  
BADILLI F. U., BEŞİKCİ A., AMASYA G., ŞEN A. T., TARIMCI M. N.  
AAPS Annual Meeting and Exposition, San Diego, United States Of America, 2 - 06 November 2014
- XXV. **Qualitative and quantitative skin effects of lipid nanoparticles**  
AMASYA G., SANDRI G., BEŞİKCİ A., BADILLI F. U., CARAMELLA C., BONFERONI M. C., TARIMCI M. N.  
AAPS Annual Meeting and Exposition, San Diego, United States Of America, 2 - 06 November 2014
- XXVI. **Inhibition of cyclooxygenase 1 enzyme by flurbiprofen loaded ophthalmic nanoparticles**  
AYDIN E., BEŞİKCİ A., BADILLI F. U., TARIMCI M. N.  
Pharmaceutical Sciences World Congress (PSWC 2014), Melbourne, Australia, 13 - 16 April 2014
- XXVII. **Niosomes as drug delivery system for cancer therapy**  
YÜKSEL N., SEZGİN BAYINDIR Z., BEŞİKCİ A., VURAL N.  
International Multidisciplinary Symposium on Drug Research & Development, 28 - 30 November 2013
- XXVIII. **Sythesis, Biological and Computational Evaluation of Novel N-(3-Substituted-benzylidene-2-oxoindolin-5-yl) acetamide Derivatives As Inhibitors of c-Src Tyrosine Kinase**  
KILIÇ KURT Z., BEŞİKCİ A., ÖLGEN S.  
10th International Symposium on Pharmaceutical Sciences, Ankara, Turkey, 26 - 29 June 2012, pp.186
- XXIX. **Oral paclitaxel delivery with niosomes**  
SEZGİN BAYINDIR Z., BEŞİKCİ A., YÜKSEL N.  
International Symposium on Pharmaceutical Sciences ISOPS 10th, 26 - 29 June 2012
- XXX. **Synthesis, Biological and Computational Evaluation of Novel 1,3,5-Substituted Indolin-2-one Derivatives as Inhibitors of Src Family Kinases**  
KILIÇ KURT Z., BEŞİKCİ A., ÖLGEN S.  
7th Eurasian Meeting On Heterocyclic Chemistry, İstanbul, Turkey, 17 - 21 June 2012, pp.73
- XXXI. **Niosomes for paclitaxel delivery**  
SEZGİN BAYINDIR Z., BEŞİKCİ A., YÜKSEL N.  
17th International Symposium on Biomedical Science and Technology (BIOMED), 23 - 25 November 2011
- XXXII. **Niosomal Paclitaxel Development characterization and in vivo comparision with marketed formulation**

SEZGİN BAYINDIR Z., BEŞİKCİ A., YÜKSEL N.

3rdPharmsciFair, 13 June 2011

- XXXIII. **Glucosamine increases hexosamine biosynthesis and O-linked N-acetylglucosamine in the heart, and leads to metabolic alterations similar to those seen in diabetic cardiomyopathy**  
Fulop N., Laczy B., BEŞİKCİ A., Des Rosiers C., Marchase R. B., Chatham J. C.  
45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes, Vienna, Austria, 30 September - 02 October 2009, vol.52
- XXXIV. **The Effect of Carvedilol on Substrate Metabolism in C2C12 Cells**  
BEŞİKCİ A., ÖZÇELİKAY A. T., Süzmeçelik E., İrat A. M.  
Heart Failure, Nice, France, 30 May - 02 June 2009
- XXXV. **Inhibition of matrix metalloproteinases reduces streptozotocin-induced diabetic cardiomyopathy**  
Sariahmetoglu M., Koksoy A., BİLGİNOĞLU A., BEŞİKCİ A., Turan B., Schulz R.  
19th World Congress of the International-Society-for-Heart-Research, Bologna, Italy, 22 - 25 June 2007, vol.42
- XXXVI. **Regulation of cardiac substrate utilization by protein O-glycosylation**  
Fulop N., BEŞİKCİ A., Marchase R. B., Chatham J. C.  
19th World Congress of the International-Society-for-Heart-Research, Bologna, Italy, 22 - 25 June 2007, vol.42
- XXXVII. **The Effects of Prediabetes on Responsiveness and Expression of Cardiac Beta-adrenoceptors**  
GÜNER Ş., ARIOĞLU İNAN E., ÖZAKCA GÜNDÜZ I., BEŞİKCİ A., ALTAN V. M., ÖZÇELİKAY A. T.  
2nd International Congress on Prediabetes and the Metabolic Syndrome, 25 - 28 April 2007
- XXXVIII. **The effects of chronic trimetazidine treatment on mechanical parameters and fatty acid oxidation in 14 week diabetic rat hearts**  
BEŞİKCİ A., GÜNER Ş., ARIOĞLU İNAN E., ÖZAKCA GÜNDÜZ I., ÖZÇELİKAY A. T., ALTAN V. M.  
Society for Heart and Vascular Metabolism. 4th Annual Metting, 6 - 09 September 2006
- XXXIX. **Substrate Metabolism and Function of Fructose-fed rat heart**  
GÜNER Ş., BEŞİKCİ A., ARIOĞLU İNAN E., ÖZAKCA GÜNDÜZ I., ALTAN V. M., ÖZÇELİKAY A. T.  
Society for Heart and Vascular Metabolism. 4th Annual Metting, 6 - 09 September 2006
- XL. **gAd-globular head domain of adiponectin increases fatty acid oxidation in newborn rabbit hearts**  
BEŞİKCİ A., Lopaschuk G.  
25th Annual Meeting of the North American Section of the International-Society-for-Heart-Research, Connecticut, United States Of America, 28 June - 01 July 2003, vol.35
- XLI. **The gAd-globular head domain of adiponectin improves mechanical function of the rabbit heart by stimulating glucose oxidation**  
BEŞİKCİ A., Altarejos J., Lopaschuk G.  
American-Heart-Association Abstracts From Scientific Sessions, CHICAGO, ILLINOIS, 17 - 20 November 2002, vol.106, pp.262

## Supported Projects

Kılçigil G., Beşikci A., Güven Çiloğlu B., Şen H. T., Çelik İ., Project Supported by Higher Education Institutions, SARS-CoV-2 Main proteaz (Mpro) inhibitörü yeni benzimidazol türevlerinin in silico tasarım, sentez ve biyolojik aktivite değerlendirmesi, 2021 - 2023

Elhan A. H., Onay-Besikci A., Azap A., Memikoğlu K. O., Çinar G., Akdemir Kalkan I., Özyüncü N., TUBITAK Project, Kinolon Kullanımı ve Qt Aralığı Uzaması: Risk Değerlendirmesi ve Klinik Eczacının Olası Rolü, 2020 - 2021

Badıllı F. U., Beşikci A., Aksu N. B., Kargılı Şen A., Project Supported by Higher Education Institutions, Tasarımla Kalite (QbD) Yaklaşımı ile Yarı Katı Lipit Nanopartikül Dispersyonlarının Geliştirilmesi ve İn vitro - İn vivo Değerlendirilmesi, 2019 - 2020

Onay-Besikci A., TUBITAK Project, İvabradinin Kardiyovasküler Pleiotropik Etkilerinin ve Bu Etkilere Aracılık Eden Mekanizmaların Streptozotosin Diyabet Modelinde İncelenmesi, 2016 - 2020

GÜVEN B., BEŞİKCİ A., TUBITAK Project, Bir Biased Agonist Olarak Karvedilol: Metabolik Sonuçlar Ve Mitokondriyel Biyojenezin Hücre Dizilerinde Değerlendirilmesi, 2018 - 2019

Beşikci A., Kaykı Mutlu G., Arıoğlu İnan E., TUBITAK Project, Streptozotosin diabetik ratlarda kardiyak beta adrenerjik reseptör yanıtlarında leptinin olası rolü, 2015 - 2018

Beşikci A., Kılçigil G., TUBITAK Project, Benzimidazol Yapısı Taşıyan Yeni Bazı Bileşiklerin Sentezi İle EGFR Kinaz Aktiviteleri Üzerine Etkilerinin Değerlendirilmesi, 2015 - 2017

Beşikci A., Karataş A., Algan A. H., TUBITAK Project, Etken madde salımı amacıyla polimerik nanotübüler yapıların hazırlanması ve karakterizasyonu, 2013 - 2016

BEŞİKÇİ A., TUBITAK Project, Kronik Yara Tedavisinde Etkili Elektro Çekim Tekniği İle Hazırlanmış Nanolif Yara Örtülerinin Geliştirilmesi, 2012 - 2014

Onay-Besikci A., Badilli F. U., TUBITAK Project, Kalsipotriol ve Klobetazol Propionatın Sabit Dozda Kombine Kullanımının in vitro Antipsoriyatik Etkinliğinin İnsan Epidermal Keratinosit Hücrelerinde Değerlendirilmesi, 2011 - 2012

Onay-Besikci A., Özçelikay A. T., TUBITAK Project, Beta Adrenerjik Rezeptör Blokeri İlaçların Kalbin Substrat Metabolizması Üzerindeki Etkilerinin Miyosit Hücre Kültürlerinde İncelenmesi, 2008 - 2009

BEŞİKÇİ A., TUBITAK Project, Paklitakselin niozom formülasyonlarının hazırlanması in vitro ve in vivo olarak değerlendirilmesi, 2007 - 2009

Onay-Besikci A., Özçelikay A. T., TUBITAK Project, Tip 1 diabet ve insulin rezistansı modellerinde mekanik ve metabolik değişimler ve bunların metabolik yaklaşımla tedavisi, 2004 - 2006

## Metrics

Publication: 85

Citation (WoS): 696

Citation (Scopus): 750

H-Index (WoS): 14

H-Index (Scopus): 15

## Scholarships

2219 Postdoctoral research, TUBITAK, 2006 - 2006

Graduate study abroad, YOK, 1998 - 2000